The study was presented by Francesca Capotosti, PhD, of AC Immune at the International Conference on Alzheimer's and Parkinson's Diseases in Lisbon. The researchers found that the company's Morphomer a-syn PET tracer demonstrated excellent sensitivity for human Parkinson's disease-brain derived alpha-synuclein (a-syn), according to the company. AC Immune said it's now progressing with a phase I trial for the PET tracer.
In addition, AC Immune is also beginning preclinical development of its oral small-molecule Morphomer a-syn inhibitors and SupraAntigen a-syn antibodies as therapeutic candidates for Parkinson's and other related diseases.
Copyright © 2019 AuntMinnieEurope.com